WO2005063759A1 - Procede servant a preparer des hybrides de pyrrolo[2, 1-c] [1, 4] benzodiazepine - Google Patents
Procede servant a preparer des hybrides de pyrrolo[2, 1-c] [1, 4] benzodiazepine Download PDFInfo
- Publication number
- WO2005063759A1 WO2005063759A1 PCT/IN2003/000462 IN0300462W WO2005063759A1 WO 2005063759 A1 WO2005063759 A1 WO 2005063759A1 IN 0300462 W IN0300462 W IN 0300462W WO 2005063759 A1 WO2005063759 A1 WO 2005063759A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- pyrrolo
- benzo
- imidazol
- compound
- Prior art date
Links
- 0 C*Oc(cc1)ccc1C1=Nc2ccccc2*1 Chemical compound C*Oc(cc1)ccc1C1=Nc2ccccc2*1 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to novel pyrrolo[2, 1-c] [ 1,4] benzodiazepine hybrids as well as processes for the preparation of novel pyrrolo[2, 1-c] [ 1,4] benzodiazepine hybrids. More particularly, present invention relates to a process for the preparation of novel pyrrolo[2, 1-c] [ 1,4] benzodiazepine hybrids as DNA sequence selective agents which are useful as potential antitumour agents. In particular, the present invention relates to a process for the preparation of new pyrrolo [2,1- c] [ 1,4] benzodiazepine hybrids as potential antitumour agents.
- the present invention also provides a process for the preparation of 7-methoxy- 8- ⁇ n-[41H- benzo [d] imidazolo - 2 yl phenoxy] alkyl ⁇ - oxy (llaS) 1,2,3,-11 a tetrahydro- 5H- pyrrolo [ 2,1- c] 1, 4] benzodiazepin- 5 one V, 7- methoxy- 8- (n - ⁇ 4-[6- (4-methyl hexahydro- 1- pyrainyl)- 1 H- benzo [d] imidazol- 2 yl] phenoxy ⁇ alkyl)- oxy- (l laS) - 1,2,3, 11a - tetrahydro - 5 H- pyrrolo 1 H- benzodiazepin 5 one V, 7- methoxy- 8 (n- ⁇ 4- [6-4 methyl hexahydro-1 prazinyl)- lH-benzo [d] imidazol
- the present process provides a process for preparation of pyrrolo [ 2,1-c] 1, 4] benzodiazepine hybrids of formula V
- n 3 to 5 by known methods, reacting the said amino compound of formula IV with conventional deprotecting agents in to produce pyrrolo [ 2,1-c] 1, 4] benzodiazepine hybrids of formula V, wherein "n" is as defined above.
- the present invention provides a process for preparation of pyrrolo [ 2,1-c] 1, 4] benzodiazepine hybrids of formula IX
- the present invention provides a process for preparation of pyrrolo [ 2,1-c] 1, 4] benzodiazepine hybrids of formula XTII
- Example 1 Compound 4-[lH-benzo [d] imidazol-2-yl] phenol I (210 mg, 1 mmol) and (2S)-N-4-(3-bromobutyloxy)-5-methoxy-2-nitrobenzoyl] pyrrolidin-2-carboxaldehyde diethyl thioacetal of formula II (521 mg, 1 mmol) was taken in dry DMF (lOmL). K2CO3 (690mg, 5mmol) was added and the mixture was stirred for 12 to 24hrs.
- Example 2 Compound 4-[lH-benzo [d] imidazol-2-yl] phenol I (210 mg, 5 mmol) and (2S)-N-[4-(4-bromobutyloxy)-5-methoxy-2-nitrobenzoyl] pyrrolidin-2-carboxaldehyde diethyl thioacetal of formula II (535 mg, 1 mmol) was taken in dry DMF (lOmL). K 2 CO 3 (690 mg, 5 mmol) was added and the mixture was stirred for 12 to 24hrs. The reaction mixture was poured in to ice-water then solid was formed and it was filtered and aqueous media was extracted with EtOAc and CHC1 3 (50 mL).
- Example 3 Compound 4-[lH-benzo [d] imidazol-2-yl] phenol I (210 mg, 1 mmol) and (2S)-N-[4-(5-bromobutyloxy)-5-methoxy-2-nitrobenzoyl] pyrrolidin-2-carboxaldehyde diethyl thioacetal of formula II (549 mg, 5 mmol) was taken in dry DMF (lOmL), K 2 CO 3 (690 mg, 5 mmol) was added and the mixture was stirred for 12-24 th . The reaction mixture was poured in to ice-water then solid was formed and it was filtered and aqueous media was extracted with EtOAc and CHC1 3 (50 mL).
- Example 4 Compound 4-[6-(4-methylhexahydro-l-pyrazinyl)-lH-benzo [d] imidazol-2-yl] phenol VI (328 mg, 1 mmol) and (2S)-N-[4-(3-bromobutyloxy)-5-methoxy-2- nitrobenzoyl] pyrrolidin-2-carboxaldehyde diethyl thioacetal of formula II (521 mg, 1 mmol) was taken in dry DMF (lOmL). K 2 CO 3 (690 mg, 5 mmol) was added and the mixture was stirred for 12-24*.
- reaction mixture was poured in to ice-water then solid was formed and it was filtered and aqueous media was extracted with EtOAc and CHC1 3 (50 mL), then the extracted solution was evaporated in vacuum to obtain the solid compound. Two solids were combined and the crude material was.
- reaction mixture was diluted with EtOAc (30mL) and filtered through a celite bed.
- the clear brown organic supernatant was extracted with saturated 5% NaHCO 3 (20mL), brine (20mL) and the combined organic phase was dried (Na2SO4).
- Example 5 Compound 4-[6-(4-methylhexahydro-l-pyrazonyl)-lH-zenzo [d] imidazol-2-yl] phenol VI (328 g, 1 mmol) and (2S)-N-4-(4-bromobutyloxy)-5-methoxy-2- nitrobenzoyl] pyrrolidin-2-carboxaldehyde diethyl thioacetal of formula II (535 mg, 1 mmol) was stirred for 12-24 .
- reaction mixture was then adjusted to pH 8 caref lly with saturated NaHCO 3 solution, diluted with ethyl acetate, filtered through celite and extracted.
- the combined organic phase was dried over Na 2 SO 4 , and evaporated under vacuum to afford the crude compound (2S) -N- ⁇ 4-(4-[6-(4- methylhexahy dro- 1 -pyraziny 1 )- 1 H-benzo [d]imidazol-2-yl] imidazol-2- yl]phenoxy)propoxy-5-metJ ⁇ oxy-2-aminobenzoyl ⁇ pyrrolidine-2-carboxaldehyde diethyl thioacetal VIII.
- reaction mixture was diluted with EtOAc (30mL) and filtered through a celite bed.
- the clear brown organic supernatant was extracted with saturated 5% NaHCO 3 (20mL), brine (20mL) and the combined organic phase was dried ( a2SO ).
- Example 6 Compound 4-[6-(4-methylhexahydro-l-pyrazonyl)-lH-zenzo [d] imidazol-2-yl] phenol VI (328 g, 5 mmol) and (2S)-N-4-(5-bromobutyloxy)-5-methoxy-2- nitrobenzoyl] pyrrolidin-2-carboxaldehyde diethyl thioacetal of formula II (549 mg, 1 mmol) was taken in dry DMF (lO L). K2CO3 (690mg, 5 mmol) was added and the
- reaction mixture was diluted with EtOAc (30mL) and filtered through a celite bed.
- the clear brown organic supernatant was extracted with saturated 5% NaHCO 3 (20mL), brine (20mL) and the combined organic phase was dried (Na2SO 4 ).
- Example 7 • Compound 4-[6-(4-methylhexahydro-l-pyrazonyl)-lH-zenzo [d] imidazol-2-yl] phenol X (342 g, 5 mmol) and (2S)-N-4-(3-bromobutyloxy)-5-methoxy-2- nitrobenzoyl] pyrrolidin-2-carboxaldehyde diethyl thioacetal of formula II (521 mg, 1 mmol) was taken in dry DMF (lOmL). K 2 CO 3 (690mg, 5 mmol) was added and the mixture was stirred for 12-24*.
- reaction mixture was poured in to ice-water then solid was formed and it was filtered and aqueous media was extracted with EtOAc and C ⁇ C1 3 (50 mL), then the extracted solution was evaporated in vacuum to obtain the solid compound. Two solids were combined and the crude material was.
- reaction mixture was diluted with EtOAc (30mL) and filtered through a celite bed.
- the clear brown organic supernatant was extracted with saturated 5% NaHCO 3 (20mL), brine (20mL) and the combined organic phase was dried (Na 2 SO 4 ).
- Example 8 Compound 4-[6-(4-methylhexahydro-l-pyrazonyl)-lH ⁇ zenzo [d] imidazol-2-yl] phenol X (342 g, 5 mmol) and (2S)-N-4-(4-bromobutyloxy)-5-methoxy-2- nitrobenzoyl] pyrrolidin-2-carboxaldehyde diethyl thioacetal of formula II (535 mg, 1 mmol) was taken in dry DMF (lOmL). K 2 CO 3 (690mg, 5 mmol) was added and the mixture was stirred for 12-24*.
- reaction mixture was poured in to ice-water then solid was formed and it was filtered and aqueous media was extracted with EtOAc and CHC1 3 (50 mL), then the extracted solution was evaporated in vacuum to obtain the solid compound. Two solids were combined and the crude material was.
- reaction mixture was diluted with EtOAc (30mL) and filtered through a celite bed.
- the clear brown organic supernatant was extracted with saturated 5% NaHCO 3 (20mL), brine (20mL) and the combined organic phase was dried (Na 2 SO ).
- Example 9 Compound 4-[6-(4-methylhexahydro-l-pyrazonyl)-lH-zenzo [d] imidazol-2-yl] phenol X (342 g, 1 mmol) and (2S)-N-4-(5-bromobutyloxy)-5-methoxy-2- nitrobenzoyl] pyrrolidin-2-carboxaldehyde diethyl thioacetal of formula II (549 mg, 5 mmol) was taken in dry DMF (lOmL). K 2 CO 3 (690mg, S mmol) was added and the mixture was stirred for 12-24*.
- reaction mixture was poured in to ice-water then solid was formed and it was filtered and aqueous media was extracted with EtOAc and CHC1 3 (50 mL), then the extracted solution was evaporated in vacuum to obtain the solid compound. Two solids were combined and the crude material was.
- Cytotoxicity Compound IX was evaluated for the primary anti-cancer activity (Table- 1) and in vitro against sixty human tumour cells derived from nine cancer types (leukemia, non-small- cell lung, colon, CNS, melanoma, ovarian, prostate, and breast cancer). For each compound, dose response curves for each cell line were measured at a minimum of five concentrations at 10 fold dilutions. A protocol of 48 h continuous drug exposure was used and a sulforhodamine B (SRB) protein assay was used to estimate cell viability or growth. The concentration causing 50% cell growth inhibition (GI50), total cell growth control was calculated.
- SRB sulforhodamine B
- the mean graph midpoint values of loglO TGI and loglO LC50 as well as log 10 GI50 for VI are listed in Table 2. As demonstrated by mean graph pattern, compound IV exhibits an interesting profile of activity and selectivity for various cell lines. The mean graph mid point of loglO TGI and loglO LC50 showed similar pattern to the loglO Gl 50 mean graph mid points. Table 1 : in vitro one dose primary anticancer assay a of PBD hybrid formula IX as representative compound.
- Table 2. loglO GI50 loglO TGI and LC50 mean graphs midpoints (MG_MID) of in vitro cytotoxicity data for the compound IX as representative compound against human tumour cell lines.
- Each cancer type represents the average of six to nine different cancer cell lines.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0614750A GB2424883B (en) | 2003-12-31 | 2003-12-31 | Process for preparing pyrrolo[2, 1-c] [1,4] benzodiazepine hybrids |
AU2003300718A AU2003300718A1 (en) | 2003-12-31 | 2003-12-31 | Process for preparing pyrrolo(2, 1-c) (1, 4) benzodiazepine hybrids |
JP2005512761A JP4520411B2 (ja) | 2003-12-31 | 2003-12-31 | ピロロ[2,1−c][1,4]ベンゾジアゼピン・ハイブリッドの調製方法 |
PCT/IN2003/000462 WO2005063759A1 (fr) | 2003-12-31 | 2003-12-31 | Procede servant a preparer des hybrides de pyrrolo[2, 1-c] [1, 4] benzodiazepine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2003/000462 WO2005063759A1 (fr) | 2003-12-31 | 2003-12-31 | Procede servant a preparer des hybrides de pyrrolo[2, 1-c] [1, 4] benzodiazepine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005063759A1 true WO2005063759A1 (fr) | 2005-07-14 |
Family
ID=34717579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2003/000462 WO2005063759A1 (fr) | 2003-12-31 | 2003-12-31 | Procede servant a preparer des hybrides de pyrrolo[2, 1-c] [1, 4] benzodiazepine |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP4520411B2 (fr) |
AU (1) | AU2003300718A1 (fr) |
GB (1) | GB2424883B (fr) |
WO (1) | WO2005063759A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008099416A2 (fr) * | 2007-02-13 | 2008-08-21 | Council Of Scientific & Industrial Research | Nouveaux hybrides de pyrrolo[2,1-c][1,4]benzodiazépine liée à un benzothiazole et un benzoxazole en tant que nouveaux agents antitumoraux et leur procédé de préparation |
JP2009515870A (ja) * | 2005-11-10 | 2009-04-16 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ | 新規なピロロ[2,1−c][1,4]ベンゾジアゼピンハイブリッドおよびその調製のための方法 |
WO2009110000A1 (fr) * | 2008-03-05 | 2009-09-11 | Council Of Scientific & Industrial Research | Nouveaux hybrides de naphtalimide-benzimidazole comme agents antitumoraux potentiels et leur procédé de préparation |
WO2009113085A1 (fr) * | 2008-03-11 | 2009-09-17 | Council Of Scientific & Industrial Research | Nouveaux hybrides de pyrrolo[2,1-q[1,4] benzodiazépine liés au un cycle benzimidazole en tant qu’agents anti-tumoraux et leurs procédés de préparation |
WO2009118748A1 (fr) * | 2008-03-26 | 2009-10-01 | Council Of Scientific & Industrial Research | Hybrides de pyrrolo[2,1-q[1.^benzodiazépine liés à l'isoxazoline en tant qu'agents anti-cancéreux potentiels et leurs procédés de fabrication |
WO2010058414A1 (fr) * | 2008-11-19 | 2010-05-27 | Council Of Scientific & Industrial Research | Nouveaux dérivés de pyrrolo[2,1-c][1,4]benzodiazépine possédant des chaînes latérales dithiocarbamate et leur procédé de préparation |
US10787463B2 (en) | 2015-07-21 | 2020-09-29 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012508A2 (fr) * | 1998-08-27 | 2000-03-09 | Spirogen Limited | Composes |
-
2003
- 2003-12-31 WO PCT/IN2003/000462 patent/WO2005063759A1/fr active Application Filing
- 2003-12-31 AU AU2003300718A patent/AU2003300718A1/en not_active Abandoned
- 2003-12-31 JP JP2005512761A patent/JP4520411B2/ja not_active Expired - Fee Related
- 2003-12-31 GB GB0614750A patent/GB2424883B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012508A2 (fr) * | 1998-08-27 | 2000-03-09 | Spirogen Limited | Composes |
Non-Patent Citations (7)
Title |
---|
KAMAL A ET AL: "Design, Synthesis, and Evaluation of New Non-Crosslinking Pyrrolobenzodiazepine Dimers with Efficient DNA Binding Ability and Potent Antitumor Activity", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 45, 2002, pages 4679 - 4688, XP002249808, ISSN: 0022-2623 * |
KELLY D P ET AL: "DNA BINDING COMPOUNDS. VI SYNTHESIS AND CHARACTERIZATION OF 2,5'-DISUBSTITUTED BIBENZIMIDAZOLES RELATED TO THE DNA MINOR GROOVEBINDER HOECHST 33258", AUSTRALIAN JOURNAL OF CHEMISTRY, XX, XX, vol. 47, no. 9, 1994, pages 1751 - 1769, XP000826532, ISSN: 0004-9425 * |
SUN Q ET AL: "STRUCTURE ACTIVITY OF TOPOISOMERASE I POISONS RELATED TO HOECHST 33342", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 4, no. 24, 1994, pages 2871 - 2876, XP002066290, ISSN: 0960-894X * |
TAWAR U. ET AL.: "Influence on phenyl ring disubstitution on bisbenzimidazole and terbenzimidazole cytotoxicity: Synthesis and biological evaluation as radioprotectors", J. MED. CHEM., vol. 46, no. 18, 28 August 2003 (2003-08-28), pages 3785 - 3792, XP002288100 * |
THURSTON D E ET AL: "SYNTHESIS OF DNA-INTERACTIVE PYRROLO2,1-C1,4BENZODIAZEPINES", CHEMICAL REVIEWS, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 94, 1994, pages 433 - 465, XP001026336, ISSN: 0009-2665 * |
THURSTON D E ET AL: "Synthesis of Sequence-Selective C8-Linked Pyrrolo(2,1-c)(1,4)benzodia zepine DNA Interstrand Cross-Linking Agents", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 61, no. 23, 1996, pages 8141 - 8147, XP002272010, ISSN: 0022-3263 * |
TURNER P. R. AND DENNY W. A.: "The mutagenic properties of DNA minor-groove binding ligands", MUTATION RESEARCH, vol. 355, no. 1, 1996, pages 141 - 169, XP002288099 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009515870A (ja) * | 2005-11-10 | 2009-04-16 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ | 新規なピロロ[2,1−c][1,4]ベンゾジアゼピンハイブリッドおよびその調製のための方法 |
GB2459808B (en) * | 2007-02-13 | 2011-09-14 | Council Scient Ind Res | Benzothiazole and benzoxazole linked pyrrolo [2,1-C] [1,4] benzodiazepine hybrids as novel antitumour agents and process for the preparation thereof |
WO2008099416A3 (fr) * | 2007-02-13 | 2008-10-16 | Council Scient Ind Res | Nouveaux hybrides de pyrrolo[2,1-c][1,4]benzodiazépine liée à un benzothiazole et un benzoxazole en tant que nouveaux agents antitumoraux et leur procédé de préparation |
WO2008099416A2 (fr) * | 2007-02-13 | 2008-08-21 | Council Of Scientific & Industrial Research | Nouveaux hybrides de pyrrolo[2,1-c][1,4]benzodiazépine liée à un benzothiazole et un benzoxazole en tant que nouveaux agents antitumoraux et leur procédé de préparation |
GB2459808A (en) * | 2007-02-13 | 2009-11-11 | Council Scient Ind Res | Novel benzothiazole and benzoxazole linked pyrrolo (2,1-C) (1,4) benzodiazepine hybrids as novel antitumour agents and process for the preparation thereof |
US8063204B2 (en) | 2007-02-13 | 2011-11-22 | Council Of Scientific & Industrial Research | Benzothiazole and benzoxazole linked pyrrolo[2,1-c] [1, 4] benzodiazepine hybrids as novel antitumour agents and process for the preparation thereof |
WO2009110000A1 (fr) * | 2008-03-05 | 2009-09-11 | Council Of Scientific & Industrial Research | Nouveaux hybrides de naphtalimide-benzimidazole comme agents antitumoraux potentiels et leur procédé de préparation |
GB2469980B (en) * | 2008-03-05 | 2012-02-22 | Council Scient Ind Res | Naphthalimide-benzimidazole hybrids as potential antitumour agents and process for the preparation thereof |
GB2469980A (en) * | 2008-03-05 | 2010-11-03 | Council Scient Ind Res | Novel napthalimide-benzimidazole hybrids as potential antitumour agents and process for the preparation thereof |
WO2009113085A1 (fr) * | 2008-03-11 | 2009-09-17 | Council Of Scientific & Industrial Research | Nouveaux hybrides de pyrrolo[2,1-q[1,4] benzodiazépine liés au un cycle benzimidazole en tant qu’agents anti-tumoraux et leurs procédés de préparation |
US8835421B2 (en) | 2008-03-11 | 2014-09-16 | Council Of Scientific And Industrial Research | Benzimidazole linked pyrrolo[2,1-c[1,4] benzodiazepine hybrids as potential antitumour agents and process for the preparation thereof |
WO2009118748A1 (fr) * | 2008-03-26 | 2009-10-01 | Council Of Scientific & Industrial Research | Hybrides de pyrrolo[2,1-q[1.^benzodiazépine liés à l'isoxazoline en tant qu'agents anti-cancéreux potentiels et leurs procédés de fabrication |
US8372831B2 (en) | 2008-03-26 | 2013-02-12 | Council Of Scientific & Industrial Research | Isoxazoline linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof |
WO2010058414A1 (fr) * | 2008-11-19 | 2010-05-27 | Council Of Scientific & Industrial Research | Nouveaux dérivés de pyrrolo[2,1-c][1,4]benzodiazépine possédant des chaînes latérales dithiocarbamate et leur procédé de préparation |
US8592407B2 (en) | 2008-11-19 | 2013-11-26 | Council Of Scientific & Industrial Research | Pyrrolo[2,1-c][1,4] benzodiazepine derivatives with dithiocarbamate side chains and process for the preparation thereof |
US10787463B2 (en) | 2015-07-21 | 2020-09-29 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
US10899775B2 (en) | 2015-07-21 | 2021-01-26 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
US11420982B2 (en) | 2015-07-21 | 2022-08-23 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
Also Published As
Publication number | Publication date |
---|---|
GB2424883A (en) | 2006-10-11 |
JP2007528343A (ja) | 2007-10-11 |
AU2003300718A1 (en) | 2005-07-21 |
JP4520411B2 (ja) | 2010-08-04 |
GB0614750D0 (en) | 2006-09-06 |
GB2424883B (en) | 2008-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1608664B1 (fr) | Pyrrolo[2,1-c][1,4]benzodiazepines non-reticulees comme agents anticancereux potentiels et leur procede de preparation | |
KR100597505B1 (ko) | 4-아미노-6-페닐-피롤로[2,3-d]피리미딘 유도체 | |
EP2061795B1 (fr) | Hybrides pyrrolo[2,1-c][1,4]benzodiazépine et leur procédé de préparation | |
JP2009513525A (ja) | キナーゼ阻害剤として活性なピロロ[3,4−c]ピラゾール誘導体 | |
US7312210B2 (en) | Pyrrolo[2,1-c][1,4]benzodiazepine compounds and processes for the preparation thereof | |
US6951853B1 (en) | Process for preparing pyrrolo[2, 1-c] [1,4] benzodiazepine hybrids | |
WO2005063759A1 (fr) | Procede servant a preparer des hybrides de pyrrolo[2, 1-c] [1, 4] benzodiazepine | |
US20080064685A1 (en) | Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof | |
EP2265613B1 (fr) | Hybrides de pyrrolo[2,1-c][1, 4]benzodiazépine liée à la quinazoline en tant qu agents anticancéreux potentiels et procédé pour la préparation de ceux-ci | |
AU2005211493B8 (en) | Pyrrolo pyrimidine derivatives useful for treating proliferative diseases | |
EP1608650B1 (fr) | Derives de pyrrolo(2,1-c)(1,4)benzodiazepine lies au pyrene utiles en tant qu'agents anticancereux | |
US7056913B2 (en) | C8—linked pyrrolo[2,1-c][1,4]benzodiazepine-acridone/acridine hybrids | |
US20040192677A1 (en) | Pyrene-linked pyrrolo[2,1--c][1,4]benzodiazepine hybrids useful as anti-cancer agents | |
US6683073B1 (en) | Pyrimidine linked pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents | |
WO2005063760A1 (fr) | Hybrides acridone/acridine de pyrrolo[2,1-c][1,4]benzodiazepine a liaison c-8 | |
WO2004087712A1 (fr) | Nouvelles pyrrolo[2,1-c][1,4]benzodiazepines a liaison pyrimidine utilisees comme agents antitumoraux potentiels | |
WO2010052732A1 (fr) | Cinnamido-pvrrolor[2,1-c][1,4]benzodiazépines utiliées comme agents anticancéreux potentiels et processus de préparation de ces composés | |
WO2009113084A1 (fr) | Dimères de pyrrolo[2,1-c][1,4] benzodiazépine liés un cycle pipérazine substitués par c2-fluoré et son procédé de préparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3821/DELNP/2005 Country of ref document: IN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005512761 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0614750.8 Country of ref document: GB Ref document number: 0614750 Country of ref document: GB |
|
122 | Ep: pct application non-entry in european phase |